Sunday 1 June 2025

Takeda Pharmaceutical: first Japan, then the world

Pharmaceutical
Simon Wentworth
27 October 2020
takeda_hq_japan_large

If any single chart could tell the tale of Takeda's (TYO: 4502) global pharmaceutical ambitions, it would be one showing change in annual revenues.

The company, which was originally founded in Osaka in 1781, has booked an impressively consistent annual revenue figure of around $16 billion to $18 billion for the last decade.

Last year, the revenue figure was $30.2 billion, and the firm has forecast over $31 billion for the Japanese financial year ending March 2021.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

search_phase_execution_exception: [es_rejected_execution_exception] Reason: rejected execution of TimedRunnable{original=ActionRunnable#wrap[org.elasticsearch.search.SearchService$$Lambda/0x00007f9358a06958@74edb39f], creationTimeNanos=58252829854306573, startTimeNanos=0, finishTimeNanos=-1, failedOrRejected=false} on TaskExecutionTimeTrackingEsThreadPoolExecutor[name = instance-0000000002/search, queue capacity = 1000, task execution EWMA = 26ms, total task execution time = 21.5h, org.elasticsearch.common.util.concurrent.TaskExecutionTimeTrackingEsThreadPoolExecutor@29c8a858[Running, pool size = 2, active threads = 2, queued tasks = 1000, completed tasks = 10629843]]


search_phase_execution_exception: [es_rejected_execution_exception] Reason: rejected execution of TimedRunnable{original=ActionRunnable#wrap[org.elasticsearch.search.SearchService$$Lambda/0x00007f9358a06958@37592fac], creationTimeNanos=58252829878195696, startTimeNanos=0, finishTimeNanos=-1, failedOrRejected=false} on TaskExecutionTimeTrackingEsThreadPoolExecutor[name = instance-0000000002/search, queue capacity = 1000, task execution EWMA = 115.3ms, total task execution time = 21.5h, org.elasticsearch.common.util.concurrent.TaskExecutionTimeTrackingEsThreadPoolExecutor@29c8a858[Running, pool size = 2, active threads = 2, queued tasks = 1000, completed tasks = 10629844]]search_phase_execution_exception: [es_rejected_execution_exception] Reason: rejected execution of TimedRunnable{original=ActionRunnable#wrap[org.elasticsearch.search.SearchService$$Lambda/0x00007f9358a06958@3cea3853], creationTimeNanos=58252829861962713, startTimeNanos=0, finishTimeNanos=-1, failedOrRejected=false} on TaskExecutionTimeTrackingEsThreadPoolExecutor[name = instance-0000000002/search, queue capacity = 1000, task execution EWMA = 115.3ms, total task execution time = 21.5h, org.elasticsearch.common.util.concurrent.TaskExecutionTimeTrackingEsThreadPoolExecutor@29c8a858[Running, pool size = 2, active threads = 2, queued tasks = 1000, completed tasks = 10629844]]More ones to watch >


search_phase_execution_exception: [es_rejected_execution_exception] Reason: rejected execution of TimedRunnable{original=ActionRunnable#wrap[org.elasticsearch.search.SearchService$$Lambda/0x00007f9358a06958@6b8dad29], creationTimeNanos=58252829849971877, startTimeNanos=0, finishTimeNanos=-1, failedOrRejected=false} on TaskExecutionTimeTrackingEsThreadPoolExecutor[name = instance-0000000002/search, queue capacity = 1000, task execution EWMA = 26ms, total task execution time = 21.5h, org.elasticsearch.common.util.concurrent.TaskExecutionTimeTrackingEsThreadPoolExecutor@29c8a858[Running, pool size = 2, active threads = 2, queued tasks = 1000, completed tasks = 10629843]]

Company Spotlight

A multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant bacterial infections and rare diseases.




More Features in Pharmaceutical

NICE backs broader access for AstraZeneca's chronic kidney disease treatment
30 May 2025
Sumitomo to co-promote SC Ozempic in Japan
30 May 2025
In the era of RFK Jr, pharma must turn to education in advertising
30 May 2025
EMA pressed for clearer guidance on decentralized trials
30 May 2025


Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze